KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Free Cash Flow (2016 - 2025)

Nektar Therapeutics has reported Free Cash Flow over the past 16 years, most recently at -$65.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$65.0 million for Q4 2025, down 39.3% from a year ago — trailing twelve months through Dec 2025 was -$208.7 million (down 17.78% YoY), and the annual figure for FY2025 was -$208.7 million, down 17.78%.
  • Free Cash Flow for Q4 2025 was -$65.0 million at Nektar Therapeutics, down from -$48.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for NKTR hit a ceiling of -$37.9 million in Q2 2024 and a floor of -$157.4 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$52.0 million (2023), compared with a mean of -$65.8 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 90.66% in 2021 and later surged 63.02% in 2022.
  • Nektar Therapeutics' Free Cash Flow stood at -$157.4 million in 2021, then surged by 63.02% to -$58.2 million in 2022, then increased by 18.78% to -$47.3 million in 2023, then rose by 1.35% to -$46.6 million in 2024, then crashed by 39.3% to -$65.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$65.0 million (Q4 2025), -$48.9 million (Q3 2025), and -$45.8 million (Q2 2025) per Business Quant data.